International Survey Shows Women Face 4-Year-Plus Diagnostic Delays in Autoimmune Disease at Higher Rates Than Men

Researchers fielded the multilingual survey from December 2024 through March 2025, recruiting via patient groups and social media while oversampling men and minority ethnic respondents. After multivariable adjustment for age, disease subtype, continent, and socioeconomic status, women averaged more pre-diagnosis visits and longer intervals to confirmed autoimmune or rheumatic disease, most often thyroid autoimmunity. Self-reported misclassification as psychosomatic or psychiatric conditions remained elevated among women even after these controls.

These patterns align with broader evidence of sex-biased symptom interpretation in rheumatology and endocrinology, where fragmented specialist care and limited sex-disaggregated trial data compound under-recognition. Because autoimmune diseases already affect women at roughly twice the rate of men, cumulative diagnostic delay translates into preventable organ damage and reduced workforce participation, disproportionately burdening female patients and their families.

Clinicians should apply sex-informed thresholds when evaluating fatigue, pain, or cognitive symptoms and document explicit consideration of autoimmune serologies before attributing complaints to anxiety. Patients benefit from maintaining symptom timelines and requesting second opinions or rheumatology referral when initial mental-health diagnoses fail to resolve objective findings. Future studies must link these self-reports to electronic health record timestamps and test whether targeted primary-care training shortens intervals.